CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER?NSCLC?02 (GDF?15 Antibody?MediaTed?Human?Effector?T?Cell Relocation) trial (NCT07246863). The trial ...
Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...
Researchers led by a team from Mass General Brigham and the Ragon Institute have discovered why some people living with HIV who are given a treatment called broadly neutralizing anti-HIV antibodies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback